Firefly Neuroscience Advances AI-Driven BNA Technology in Neuroscience Drug Development

Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced advancing its artificial intelligence-powered Brain Network Analytics (BNA™) technology after successful research collaborations with Takeda Pharmaceutical Company Limited (“Takeda”) and Novartis, two global leaders in pharmaceutical R&D, illustrating the value of Firefly’s AI-based technology in providing objective measures in neuroscience drug development.

“Our collaborations with Takeda and Novartis mark a pivotal step in accelerating drug development,” said Jon Olsen, Firefly’s CEO. “By using our BNA™ technology, pharmaceutical companies can leverage the additional objective measures of brain activity to enhance the design of future trials and advance their drug candidates faster toward regulatory approval. Additionally, integrating Firefly's BNA™ technology into neuroscience drug development allows researchers to reduce costs and time by precisely measuring drug effects on the brain and identifying patients most likely to respond, leading to improved clinical outcomes.”

Incorporating Firefly’s BNA™ technology into CNS drug development provides biotechnology and pharma companies with tools to enhance patient and dose selection, thus reducing cost and accelerating drug development. Firefly intends to continue leveraging its unique database and technology to expand its partnerships with neuroscience pharmaceutical companies, building on its collaborations with industry leaders like Novartis and Takeda.

“Many new drugs being developed are expensive, and there is considerable resistance from healthcare providers, governments, and insurers to absorb the high cost of new drugs without knowing who is most likely to benefit from the drug,” continued Mr. Olsen. “Firefly believes that electrophysiology-based biomarkers, like BNA, represent a significant opportunity for neuroscience drug development companies.”

Source URL : Globenewswire